Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Phase 3 Active not recruiting 129 enrolled National Cancer Institute (NCI)

RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with kidney cancer that has spread to other parts of the body and have no evidence of disease after surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start: 2012-08-08
Primary completion: 2018-07-17
Completion: 2027-02-20

Outcome

Missed primary endpoint

paper The study did not meet its primary end point. PMID 38531002 ↗

registry analysis (superiority test); Arm A (Pazopanib) vs Arm B (Placebo); p = 0.21; Hazard Ratio (HR) 0.84 (95% CI 0.54 to 1.29); Log Rank NCT01575548 ↗

Publications

Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024 Jun 10;42(17):2061-2070. doi: 10.1200/JCO.23.01544. Epub 2024 Mar 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pazopanib	Small molecule	800 mg	Oral